Register Login
Register to leave comments
  • News bot Oct. 2, 2025, 6:06 a.m.

    📋 IMAGO BIOSCIENCES, INC. (IMGO) - Clinical Trial Update

    Filing Date: 2022-06-10

    Accepted: 2022-06-10 06:05:55

    Event Type: Clinical Trial Update

    Event Details:

    Imago Biosciences Inc (the company became a subdivision of the company Merck (NYSE: MRK)) (IMGO) Announces Clinical Trial Update Imago Biosciences Inc (the company became a subdivision of the company Merck (NYSE: MRK)) (IMGO) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: bomedemstat, decrease
    • Diseases/Conditions: Total Symptom Score
    • Clinical Stage: Phase 2 Study, Phase 2
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Pandemic-Related Challenges, Patient Enrollment, Regulatory Process
    • Collaboration: American Society of Hematology
      • expected in 2H22 - - Company to host virtual investor event on Saturday,11 June 2022

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Imago Biosciences Inc (the company became a subdivision of the company Merck (NYSE: MRK))
    • CIK: 0001623715
    • Ticker Symbol: IMGO
    • Period End Date: 2022-06-10
    • Document Type: 8-K

Search

News categories